Immunovant (IMVT) Operating Income (2019)

Immunovant's (IMVT) quarterly Operating Income came in at -$512549.0 in Q3 2019, down 452.36% on a QoQ basis from -$92792.0 in Q2 2019.

Analysis

Immunovant (IMVT) Operating Income (2019) Analysis & Trends

Immunovant (IMVT) has 1 years of Operating Income data on file, last reported at -$512549.0 in Q3 2019.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Op. Inc (Qtr)
1	Vertex Pharmaceuticals	139.27 Bn	131.42 Bn	2.84 Bn	1.25 Bn
2	Regeneron Pharmaceuticals	85.55 Bn	77.56 Bn	3.93 Bn	1.29 Bn
3	Argenx Se	63.45 Bn	58.27 Bn	1.37 Bn	493.00 Mn
4	Moderna	57.73 Bn	52.59 Bn	52.00 Mn	-815.00 Mn
5	Revolution Medicines	44.08 Bn	44.08 Bn	-	-505.13 Mn
6	BeOne Medicines	39.95 Bn	34.85 Bn	1.53 Bn	325.05 Mn
7	Alnylam Pharmaceuticals	35.14 Bn	31.84 Bn	992.69 Mn	231.44 Mn
8	Royalty Pharma	28.44 Bn	27.60 Bn	-	133.12 Mn
9	Insmed	27.32 Bn	26.16 Bn	358.27 Mn	-1.55 Mn
10	Immunovant	8.04 Bn	8.04 Bn	-	-

Historic Data

Download Data

Date	Value
Sep 30, 2019	-512,549.00
Jun 30, 2019	-92,792.00